Apigenin and Hypertension: A Review of Natural Sources, Pharmacodynamic and Pharmacokinetic Evidence.

Authors

Mohammed Ajebli, Morad Hebi, Driss Ousaaid, Mourad Akdad, Zakariae Mankour, Tarik Khouya, Badreddine Moukafih, Abdeslam El Kartouti, Mohamed Eddouks

Published in

Pharmacology. Pages 1. Oct 05, 2026. Epub Oct 05, 2026.

Abstract

This review aimed to synthesize recent evidence on the pharmacological effects of APG in the management of hypertension.
A comprehensive literature search was conducted using PubMed, Scopus, Web of Science, and Google Scholar.
Pharmacokinetic studies reveal that APG exhibits poor oral bioavailability due to low solubility and extensive metabolism yet demonstrates wide tissue distribution and neuroprotective potential. It interacts with drug-metabolizing enzymes and transporters, influencing the pharmacokinetics of co-administered agents while maintaining a favorable safety profile at dietary levels. Preclinical evidence shows that APG lowers blood pressure by promoting vasodilation through TRPV4/NO pathways, attenuating oxidative stress and inflammation, and regulating genetic signaling to prevent vascular and cardiac remodeling. Toxicity studies confirm safety up to 5000 mg/kg, while additional findings highlight its beneficial modulation of gut microbiota.
APG emerges as a promising supplementary compound for hypertension management, combining vascular, molecular, and microbiome-mediated mechanisms with a strong safety margin.

PMID:
42832459
Bibliographic data and abstract were imported from PubMed on 06 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.